Erlotinib Treatment in Colorectal Cancer Suppresses Autophagy Based on <i>KRAS</i> Mutation
The <i>KRAS</i> gene is mutated in approximately 45% of colorectal cancer patients. There are currently very few targeted treatments or therapies equipped to directly inhibit <i>KRAS</i> due to its unusual structural intricacies. Erlotinib, an EGFR inhibitor, has previously been demonstrated to redu...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
MDPI AG
2024-07-01
|
| Цуврал: | Current Issues in Molecular Biology |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://www.mdpi.com/1467-3045/46/7/447 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|